Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

19. (canceled)

20. (canceled)

37. (currently amended) A sustained release dosage form comprising:

a core formulation comprising a drug and an expandable composition; and

a bilayer membrane formed around the core formulation, the bilayer membrane comprising:

an interior lipophilic membrane comprising a lipid attracting membrane forming material including a poly(ethyl cellulose) polymer and a flux enhancer, the interior membrane being formulated to soften and disintegrate as the interior membrane absorbs lipids from an environment of use; and

an exterior hydrophilic membrane comprising 35 wt% to 70 wt% of a semipermeable material permeable to the passage of an aqueous fluid, a plasticizer, and 20 wt% to 35 wt% of a compound possessing at least one peptide moiety, the exterior membrane being formulated and configured to delay disintegration of the interior membrane and lose mechanical integrity as the sustained release dosage form operates in the environment of use.

38. (original) The sustained release dosage form of claim 37, wherein the exterior hydrophilic membrane comprises:

20 wt% to 35 wt% of the compound possessing at least one peptide moiety;

35 wt% to 70 wt% of the semipermeable material;

10 wt% to 40 wt% of a plasticizer; and

0 wt% to 10 wt% of a surfactant.

39. (original) The sustained release dosage form of claim 37, wherein the hydrophilic exterior membrane comprises:

20 wt% to 35 wt% of the compound possessing at least one peptide moiety;

35 wt% to 70 wt% of a ~~member~~ semipermeable material selected from the group consisting of a cellulose acylate, cellulose diacylate, and a cellulose triacylate polymer;

10 wt% to 40 wt% of a plasticizer that increases the aqueous diffusion coefficient of the exterior hydrophilic membrane and is selected from the group consisting of glycerin, triacetin, adipic acid, azelaic acid, citric acid, triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, butyryl trihexyl citrate, polyethylene glycol, diethylene glycol dipelargonate and triethylene glycol di(2-ethylbutrate); and

0 wt% to 10 wt% of a surfactant.

40. (currently amended) The sustained release dosage form of claim 37, wherein the compound possessing at least one peptide moiety comprises ~~20 wt% to 35 wt% of the exterior membrane and comprises~~ a protein possessing a molecular weight of 1500 to 350,000.

41. (original) The sustained release dosage form of claim 38, wherein the surfactant is selected from the group consisting of an anionic, amphoteric, cationic and nonionic surfactant.

42. (original) The sustained release dosage form of claim 37, wherein the compound possessing at least one peptide moiety comprises a member selected from the group consisting of reticulin, silk, keratin, casein, lactoglobulin, prolamine, gluten, albumin, elastin, soy protein, globulin, gelatin, collagen, and zein.

43. (original) The sustained release dosage form of claim 40, wherein the protein is sized between 0.1 microns to 50 microns in one dimension.

44. (original) The sustained release dosage form of claim 37, wherein the interior lipophilic membrane comprises:

35 wt% to 70 wt% of the lipid attracting, membrane forming material;

25 wt% to 65 wt% of the flux enhancer; and

0 wt% to 10 wt% of a surfactant.

45. (canceled)

46. (original) The sustained release dosage form of claim 44, wherein the flux enhancer comprises hydroxyalkylcellulose, wherein the alkyl group comprises 1 to 6 carbon atoms.

47. (currently amended) The sustained release dosage form of claim 44, wherein the ~~lipophilic polymer comprises~~ poly(ethyl cellulose) ~~exhibiting~~ exhibits a viscosity of 3 to 350 centipoise.

48. (original) The sustained release dosage form of claim 44, wherein the flux enhancer comprises a hydroxyalkylcellulose selected from the group consisting of hydroxyethylcellulose and hydroxypropylcellulose.

49. (original) The sustained release dosage form of claim 44, wherein the surfactant comprises a member selected from the group consisting of polyoxyl 4 stearate, polypoxyl 8 stearate, polyoxyl 20 stearate, polyoxyl 30 stearate, polyoxyl 40 stearate, polyoxyl 50 stearate, polyoxyl 100 stearate, polyoxyl 4 distearate and polyoxyl 150 distearate, and wherein the number refers to the surfactant polymer length in oxyethylene units.

50. (original) The sustained release dosage form of claim 37, further comprising an exit through the bilayer membrane for delivering the drug from the dosage form.